Table 3.
Proportion of Treated Patients Who Received Treatment at Baseline and Proportion Who Crossed Over to Treatment by 12 Months*
| Therapy | Treatment at Baseline | No Treatment at Baseline, Crossed Over to Treatment by 12 Months |
|---|---|---|
| ACEI/ARB | ||
| Cases (dead) | 936 (96.6%) | 33 (3.4%) |
| Controls (alive) | 2062 (92.8%) | 159 (7.2%) |
| β-Blocker | ||
| Cases (dead) | 1018 (96.1%) | 41 (3.9%) |
| Controls (alive) | 2206 (94.6%) | 126 (5.4%) |
| Aldosterone antagonists | ||
| Cases (dead) | 118 (92.9%) | 9 (7.1%) |
| Controls (alive) | 203 (82.5%) | 43 (17.5%) |
| Anticoagulation for atrial fibrillation | ||
| Cases (dead) | 292 (95.1%) | 15 (4.9%) |
| Controls (alive) | 652 (94.4%) | 39 (5.6%) |
| ICD | ||
| Cases (dead) | 453 (88.3%) | 60 (11.7%) |
| Controls (alive) | 1016 (81.9%) | 224 (18.1%) |
| CRT | ||
| Cases (dead) | 49 (72.1%) | 19 (27.9%) |
| Controls (alive) | 121 (67.2%) | 59 (32.8%) |
| HF education | ||
| Cases (dead) | 874 (83.9%) | 168 (16.1%) |
| Controls (alive) | 1688 (75.2%) | 558 (24.8%) |
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator.
*
This table shows the proportion of those patients treated at baseline of the total patients treated and the proportion of patients with early crossover of the total patients treated.